NASDAQ:ALVR AlloVir (ALVR) Stock Forecast, Price & News $2.22 -0.05 (-2.20%) (As of 10:33 AM ET) Add Compare Share Share Today's Range$2.18▼$2.2850-Day Range$2.15▼$3.6452-Week Range$1.90▼$10.29Volume138,690 shsAverage Volume527,571 shsMarket Capitalization$252.79 millionP/E RatioN/ADividend YieldN/APrice Target$18.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media AlloVir MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside726.0% Upside$18.75 Price TargetShort InterestBearish7.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 5 Articles This WeekInsider TradingAcquiring Shares$10.99 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.73) to ($1.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.35 out of 5 starsMedical Sector253rd out of 965 stocksBiological Products, Except Diagnostic Industry33rd out of 162 stocks 3.5 Analyst's Opinion Consensus RatingAlloVir has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.75, AlloVir has a forecasted upside of 726.0% from its current price of $2.27.Amount of Analyst CoverageAlloVir has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.30% of the outstanding shares of AlloVir have been sold short.Short Interest Ratio / Days to CoverAlloVir has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in AlloVir has recently increased by 7.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlloVir does not currently pay a dividend.Dividend GrowthAlloVir does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALVR. Previous Next 3.0 News and Social Media Coverage News SentimentAlloVir has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for AlloVir this week, compared to 1 article on an average week.Search Interest12 people have searched for ALVR on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.MarketBeat Follows5 people have added AlloVir to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AlloVir insiders have bought 9,121.06% more of their company's stock than they have sold. Specifically, they have bought $10,990,762.00 in company stock and sold $119,192.00 in company stock.Percentage Held by Insiders39.97% of the stock of AlloVir is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.41% of the stock of AlloVir is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for AlloVir are expected to grow in the coming year, from ($1.73) to ($1.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AlloVir is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AlloVir is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlloVir has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AlloVir (NASDAQ:ALVR) StockAllovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.Read More ALVR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALVR Stock News HeadlinesSeptember 21, 2023 | fool.comWhy AlloVir Stock Dropped TodaySeptember 21, 2023 | americanbankingnews.comAlloVir, Inc. (NASDAQ:ALVR) Sees Large Growth in Short InterestSeptember 22, 2023 | MarketBeat Internal (Ad)Save $300 on MarketBeat All AccessMarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $300 account credit and free 30-day trial subscription today.September 15, 2023 | finance.yahoo.comWe're Keeping An Eye On AlloVir's (NASDAQ:ALVR) Cash Burn RateSeptember 12, 2023 | americanbankingnews.comAlloVir (NASDAQ:ALVR) Shares Down 1.7% August 28, 2023 | finance.yahoo.comAlloVir to Present at Upcoming Investor ConferencesAugust 18, 2023 | msn.comAlloVir spikes as Bank of America starts at Buy on lead assetAugust 18, 2023 | markets.businessinsider.comAlloVir's RSV Therapy Is Underappreciated Gem, BofA Comments On Future PotentialSeptember 22, 2023 | MarketBeat Internal (Ad)Save $300 on MarketBeat All AccessMarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $300 account credit and free 30-day trial subscription today.August 18, 2023 | msn.comB of A Securities Initiates Coverage of AlloVir (ALVR) with Buy RecommendationAugust 18, 2023 | markets.businessinsider.comBank of America Securities Initiates a Buy Rating on AlloVir (ALVR)August 8, 2023 | msn.comMorgan Stanley Reiterates AlloVir (ALVR) Overweight RecommendationAugust 6, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: AlloVir (ALVR), Cytokinetics (CYTK) and Guardant Health (GH)August 3, 2023 | finance.yahoo.comAlloVir Reports Second Quarter 2023 Financial ResultsJuly 10, 2023 | msn.comAlloVir: 'Takes One To Know One'June 29, 2023 | msn.comBlackBerry, Micron And Other Big Stocks Moving Higher In Thursday's Pre-Market SessionJune 27, 2023 | finance.yahoo.comAlloVir, Inc. (ALVR) Upgraded to Buy: Here's WhyJune 23, 2023 | finance.yahoo.comWhy Shares of AlloVir Plummeted This WeekJune 22, 2023 | nasdaq.comAlloVir Prices Public OfferingJune 22, 2023 | benzinga.comWhy AlloVir Stock Is Diving ThursdayJune 22, 2023 | investorplace.comWhy Is AlloVir (ALVR) Stock Down 23% Today?June 22, 2023 | seekingalpha.comAlloVir shares slide on pricing $75M of stock offeringJune 22, 2023 | markets.businessinsider.comPre-market Movers: PIXY, ROOT, CDMO, ALVR, KWE…June 22, 2023 | msn.comAlloVir, DigitalOcean And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionJune 22, 2023 | msn.comAlloVir Tanks after Stock OfferingJune 22, 2023 | finance.yahoo.comAlloVir Announces Pricing of Public Offering of Common StockJune 21, 2023 | msn.comAlloVir plans for $75M stock offeringSee More Headlines Receive ALVR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter. Email Address ALVR Company Calendar Last Earnings8/03/2023Today9/22/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALVR CUSIPN/A CIK1754068 Webwww.allovir.com Phone617-433-2605FaxN/AEmployees113Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.75 High Stock Price Forecast$20.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+726.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-168,710,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-74.04% Return on Assets-60.74% Debt Debt-to-Equity RatioN/A Current Ratio8.28 Quick Ratio8.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.41 per share Price / Book0.94Miscellaneous Outstanding Shares113,870,000Free Float68,356,000Market Cap$258.48 million OptionableNot Optionable Beta0.65 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. David L. Hallal (Age 57)Exec. Chairman Comp: $254.38kDr. Diana M. Brainard M.D. (Age 52)CEO & Director Comp: $978.99kMr. Vikas Sinha C.A. (Age 60)CPA, M.B.A., Pres, CFO & Director Comp: $536.21kMr. Edward Miller J.D. (Age 58)Gen. Counsel & Sec. Comp: $618.39kMr. Brett R. Hagen (Age 50)Chief Accounting Officer Mr. Dana M. Alexander (Age 47)Sr. VP of Technical Operations Dr. Ann M. Leen Ph.D. (Age 46)Chief Scientific Officer Ms. Sonia ChoiSr. VP of Corp. Affairs & Investor RelationsMr. Ugo Capolino PerlingieriHead & GM of Europe and Middle East OperationsMs. Cintia Piccina Pharm.D. (Age 50)Chief Commercial Officer More ExecutivesKey CompetitorsCompass TherapeuticsNASDAQ:CMPXZura BioNASDAQ:ZURAVigil NeuroscienceNASDAQ:VIGLDBV TechnologiesNASDAQ:DBVTFate TherapeuticsNASDAQ:FATEView All CompetitorsInsiders & InstitutionsBarclays PLCSold 17,076 shares on 9/21/2023Ownership: 0.016%California State Teachers Retirement SystemBought 11,449 shares on 8/21/2023Ownership: 0.056%Vikas SinhaSold 10,516 sharesTotal: $26,290.00 ($2.50/share)Diana BrainardSold 11,361 sharesTotal: $28,402.50 ($2.50/share)Brett R HagenSold 1,653 sharesTotal: $4,132.50 ($2.50/share)View All Insider TransactionsView All Institutional Transactions ALVR Stock - Frequently Asked Questions Should I buy or sell AlloVir stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALVR shares. View ALVR analyst ratings or view top-rated stocks. What is AlloVir's stock price forecast for 2023? 3 brokers have issued twelve-month price targets for AlloVir's shares. Their ALVR share price forecasts range from $17.00 to $20.00. On average, they anticipate the company's share price to reach $18.75 in the next twelve months. This suggests a possible upside of 726.0% from the stock's current price. View analysts price targets for ALVR or view top-rated stocks among Wall Street analysts. How have ALVR shares performed in 2023? AlloVir's stock was trading at $5.13 at the beginning of the year. Since then, ALVR stock has decreased by 55.8% and is now trading at $2.27. View the best growth stocks for 2023 here. Are investors shorting AlloVir? AlloVir saw a increase in short interest in August. As of August 31st, there was short interest totaling 8,310,000 shares, an increase of 7.6% from the August 15th total of 7,720,000 shares. Based on an average daily trading volume, of 868,900 shares, the days-to-cover ratio is presently 9.6 days. View AlloVir's Short Interest. When is AlloVir's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our ALVR earnings forecast. How were AlloVir's earnings last quarter? AlloVir, Inc. (NASDAQ:ALVR) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.03. What other stocks do shareholders of AlloVir own? Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL). When did AlloVir IPO? (ALVR) raised $252 million in an initial public offering (IPO) on Thursday, July 30th 2020. The company issued 14,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO. What is AlloVir's stock symbol? AlloVir trades on the NASDAQ under the ticker symbol "ALVR." Who are AlloVir's major shareholders? AlloVir's stock is owned by a number of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (5.84%), Artal Group S.A. (5.79%), BlackRock Inc. (2.92%), Woodline Partners LP (1.52%), American International Group Inc. (1.01%) and JPMorgan Chase & Co. (0.96%). Insiders that own company stock include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Beek Jeroen B Van, Brett R Hagen, David Hallal, Diana Brainard, Edward Miller, Ercem Atillasoy, Gilead Sciences, Inc, Jeffrey S Bornstein, John Robert Wilson, Juan Vera, Morana Jovan-Embiricos and Vikas Sinha. View institutional ownership trends. How do I buy shares of AlloVir? Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AlloVir's stock price today? One share of ALVR stock can currently be purchased for approximately $2.27. How much money does AlloVir make? AlloVir (NASDAQ:ALVR) has a market capitalization of $258.48 million. The company earns $-168,710,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. How many employees does AlloVir have? The company employs 113 workers across the globe. How can I contact AlloVir? AlloVir's mailing address is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. The official website for the company is www.allovir.com. The company can be reached via phone at 617-433-2605 or via email at ir@allovir.com. This page (NASDAQ:ALVR) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.